AMAG Pharmaceuticals — FY2016 Earnings Presentation
33 slides from AMAG Pharmaceuticals's earnings presentation, Feb 14, 2017
Slide 1: AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement
AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement February 14, 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, st
Slide 3: Today's Agenda
Today’s Agenda 3 2016 Highlights and Recent Events1 5 Value Drivers and Upcoming Potential Product Launches 4 IntrarosaTM: Further Expansion into Women’s Health 3 2016 Financial Overview 6 Q&A 2 2016 Product Performance and 2017 Growth Drivers
Slide 4: 2016 Highlights and Recent Events
2016 Highlights and Recent Events
Slide 5: 2016 Highlights and Recent Events
2016 Highlights and Recent Events Makena Drove 44% quarterly sales growth over 4Q-2015 and 33% growth year over year through: ‒ Successful launch of single-dose, preservative free formulation ‒ Expansion of Makena @Home service, including enhanced agreement with Optum Home Health Completed Mak
Slide 6: Further Expanding AMAG's Product Portfolio
Further Expanding AMAG’s Product Portfolio 6 Pregnancy & Birth Wellness Post-Menopausal Health Feraheme Makena Velo Option Cord Blood Registry Used for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) The only FDA-approved therapy to reduce recurrent
Slide 7: Makena: Strong Commercial Execution
7 $67.4 $97.2 4Q-2015 4Q-2016 Makena: Strong Commercial Execution $251.6 $334.1 2015 2016 Fourth Quarter Revenue ($M) Full Year Revenue ($M) W O M E N ’ S H E A L T H : M A K E N A 2017 Growth Drivers Continue to take share from compounders Grow Makena @Home administration Greater share of voi
Slide 8: Makena subcutaneous auto-injector and exclusivity
Makena intramuscular (IM) ‒ Only approved product to lower the risk of preterm birth ‒ Most frequent AE is injection site pain1 Makena exclusivity and patents ‒ IM orphan drug exclusivity through February 2018 ‒ Auto-injector covered by multiple issued Antares patents to 2026 ‒ Additional patent
Slide 9: CBR: Attractive Recurring Revenue Stream
9 CBR: Attractive Recurring Revenue Stream W O M E N ’ S H E A L T H : C O R D B L O O D R E G I S T R Y $24.1 $99.6 2015 2016 $118.6 2015 2016 GAAP Full Year Revenue ($M) $116.6 Non-GAAP, Pro Forma Full Year Revenue2,3 ($M) 1 Represents revenues from August 17, 2015 to December 31, 2015. CBR was ac
Slide 10: Feraheme: Differentiated Product, Expect Future Growth
10 $23.2 $26.3 4Q-2015 4Q-2016 Feraheme: Differentiated Product, Expect Future Growth $88.5 $97.1 2015 2016 Fourth Quarter Revenue1 ($M) Full Year Revenue1 ($M) 2017 Growth Drivers Continued growth in key segments Optimize net revenue per gram Prepare for expanded label to include IDA patients
Slide 11: GAAP Total Revenue and Operating Income
GAAP Total Revenue and Operating Income 11 $108.7 $151.6 +39% 1 Collaboration revenue related to the termination of AMAG’s ex-US ferumoxytol marketing partnership agreement. 3-months ended December 31 ($M) $22.7 $14.6 12-months ended December 31 ($M) 4Q-2015 4Q-2016 $418.3 $532.1 $111.2 $78.9 2015 2
Slide 12: GAAP Financial Summary
GAAP Financial Summary For the 3- and 12- Months Ended December 31 ($M, except per share data) Total revenues Costs and expenses Operating income Interest expense and other Net income (loss) before taxes Income tax expense (benefit) Net income (loss) Net income (loss) per basic share Net income (los
Slide 13: Non-GAAP Total Revenue and Adjusted EBITDA
Non-GAAP Total Revenue and Adjusted EBITDA 13 $120.6 $153.0 +27% 3-months ended December 31 ($M) $61.3 $77.4 12-months ended December 31 ($M) 4Q-2015 4Q-2016 $397.4 $549.1 $213.4 $265.7 2015 2016 +38% Makena CBRFeraheme/MuGard Collaboration revenue4 Adjusted EBITDA 1 Represents CBR revenues from Aug
Slide 14: Strong Cash Flow Generation
Strong Cash Flow Generation 14 ($M) 12/31/16 12/31/15 Cash, cash equivalents and investments $5791 $466 Principal debt outstanding Convertible senior notes (2.5%) $200 $200 Term loan facility (4.75%) 328 346 2023 senior notes (7.875%) 500 500 Total debt outstanding $1,028 $1,046 ($M) 12/31/16 12/31/
Slide 15: Strong Financial Profile, Management Team & Corporate Infrastructure
Strong Financial Profile, Management Team & Corporate Infrastructure Market Access, Analytics, and Other Commercial Functions Continuing to Expand AMAG’s Product Portfolio 15 Future Product Digital Consumer Marketing Expertise, Public Relations and Medical Affairs Women’s Health (Including Maternal
Slide 16: Intrarosa (prasterone)
IntrarosaTM (prasterone) A first-of-its-kind, non-estrogen women’s health therapy
Slide 17: Exclusive U.S. License for Intrarosa
Exclusive U.S. License for Intrarosa Will address a significant unmet need for post-menopausal women Strong safety and efficacy profile Large near-term commercial opportunity ‒ FDA approved in November 2016 ‒ 3 Orange Book listed patents out to 2031 Leverages AMAG’s current commercial platfo
Slide 18: Intrarosa: Potential to Address Significant Unmet Need
Intrarosa: Potential to Address Significant Unmet Need 18 Approximately 32M post-menopausal women in the U.S. suffer from symptoms of vulvar and vaginal atrophy (VVA)1 - 44% to 78% of women with VVA report symptoms of moderate-to-severe dyspareunia1,2 - Growing population of post-menopausal women
Slide 19: Overview: Vulvovaginal Atrophy (VVA)
Overview: Vulvovaginal Atrophy (VVA)1 19 3 2 W O M E N ’ S H E A L T H : I N T R A R O S A Intrarosa is indicated for moderate-to-severe dyspareunia (pain during intercourse), a symptom of VVA, due to menopause Post-menopausal VVA: - Common and underreported condition associated with decreased s
Slide 20: Intrarosa non-estrogen mechanism, efficacy and safety
Non-Estrogen- Based Intrarosa contains prasterone (DHEA), a precursor of hormones that is converted locally inside the vaginal cells into androgens and estrogens Does not carry the boxed warning that is currently required in the labels of all estrogen-containing vaginal therapies ‒ Class labelin
Slide 21: Intrarosa: Sizable Untapped Market for Treating Dyspareunia
Affected, but not yet seeking treatment Utilizing OTC treatments Previous estrogen therapy users Intrarosa: Sizable Untapped Market for Treating Dyspareunia 21 Currently on Rx estrogen therapy Safety concerns about estrogen- containing treatment options Efficacy and/or safety concerns about estrogen
Slide 22: Intrarosa Serves Significant Unmet Medical Need
Intrarosa Serves Significant Unmet Medical Need 22 1.7 M on estrogen therapy2 Local (intra-vaginal) estrogen therapies = sales of >$1B per year1 Brand(s) Current Intra-vaginal Therapies Intrarosa Administration Vaginal insert or cream by applicator Vaginal insert by applicator Indication Approved fo
Slide 23: Leverages AMAG's Current Commercial Platform
Leverages AMAG’s Current Commercial Platform Leverage existing AMAG commercial and medical affairs teams - Deep relationships and experience with the OB/GYN community and women’s health KOLs - Successful patient access and commercial analytics platform - Strong record of consistent growth (40% in
Slide 24: AMAG: At the Nexis of Key Drivers in Women's Health
AMAG: At the Nexis of Key Drivers in Women’s Health Science Patients Healthcare Providers W O M E N ’ S H E A L T H : I N T R A R O S A Awareness-building capabilities and novel product create transformational opportunity New mechanism of action New therapeutic class Only non-estrogen therapy
Slide 25: Intrarosa: Designed to Build Long-Term Shareholder Value
• $50M upfront cash payment and 600K shares of AMAG stock • Up to $10M on delivery of commercial supply for launch • $10M on the first anniversary of the effective date of the agreement • Sales milestones • $15M payment when net sales exceed $150M annually • $30M payment when net sales exceed $300M
Slide 26: Upcoming Value Drivers and Potential Product Launches
Upcoming Value Drivers and Potential Product Launches Frank Thomas President and Chief Operating Officer
Slide 27: AMAG Portfolio: Multiple Value Drivers
AMAG Portfolio: Multiple Value Drivers 27 Milestone 2017 2018 MAKENA AUTO-INJECTOR PROGRAM Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Topline PK data sNDA submission Expected FDA action and commercial launch FERAHEME IDA LABEL EXPANSION Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Enrollment completed Topline data sNDA submission Expected
Slide 28: Key Product Launch Milestones
Key Product Launch Milestones 28 Makena subcutaneous auto-injector Velo (severe preeclampsia) IDA (non-CKD) R ev e nu e Today 2017 2018 2019 2020 5 Potential Product Launches over Next 4 Years
Slide 29: AMAG Pharmaceuticals Q&A
AMAG Pharmaceuticals Q&A February 14, 2017
Slide 30: Appendix
Appendix
Slide 31: Reconciliation of GAAP to Non-GAAP 2016 Results
Reconciliation of GAAP to Non-GAAP 2016 Results 31 ($M) GAAP operating income Purchase accounting adjustments related to CBR deferred revenue Non-cash collaboration revenue Depreciation & intangible asset amortization Inventory reserve Non-cash inventory step-up adjustments Stock-based compensation
Slide 32: Share Count Reconciliation
Share Count Reconciliation 32 (M) Weighted average basic shares outstanding Employee equity incentive awards Convertible notes Warrants GAAP diluted shares outstanding Employee equity incentive awards Convertible notes Effect of bond hedge and warrants Non-GAAP diluted shares outstanding 4Q-2016 4Q-
Slide 33: AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement
AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement February 14, 2017